E-LIB Suche - Ergebnisse für: Spigel, David

1

Modified FOLFOX6 plus bevacizumab with and without nivoluma..:

Lenz, Heinz-Josef ; Parikh, Aparna ; Spigel, David R...
Journal for ImmunoTherapy of Cancer. 12 (2024) 3 - p. e008409 , 2024

Link: https://doi.org/10.1136/..

2

A phase 2 study of AZD4635 in combination with durvalumab o..:

Falchook, Gerald S. ; Reeves, James ; Gandhi, Sunil...
Cancer Immunology, Immunotherapy. 73 (2024) 4 - p. , 2024

Link: https://doi.org/10.1007/..

3

PP01.104 Vebreltinib Efficacy In METex14 Mutant NSCLC With ..:

Awad, Mark M. ; Devarakonda, Siddhartha ; Yang, Jin-Li...
Journal of Thoracic Oncology. 19 (2024) 7 - p. e45-e46 , 2024

Link: https://doi.org/10.1016/..

4

Tislelizumab plus chemotherapy versus placebo plus chemothe..:

Qiu, Miao-Zhen ; Oh, Do-Youn ; Kato, Ken...
BMJ. , 2024

Link: https://doi.org/10.1136/..

5

MyPathway human epidermal growth factor receptor 2 basket s..:

Christopher J Sweeney ; John D Hainsworth ; Ron Bose...
doi:10.25418/crick.25019936.v1. , 2024

Link: https://doi.org/10.25418..

6

MyPathway human epidermal growth factor receptor 2 basket s..:

Christopher J Sweeney ; John D Hainsworth ; Ron Bose...
doi:10.25418/crick.25019936.v1. , 2024

Link: https://doi.org/10.25418..

7

Durable responders in advanced NSCLC with elevated TMB and ..:

Huang, Richard S P ; Carbone, David P ; Li, Gerald...
Journal for ImmunoTherapy of Cancer. 11 (2023) 1 - p. e005801 , 2023

Link: https://doi.org/10.1136/..

8

Safety of First-Line Nivolumab Plus Ipilimumab in Patients ..:

Paz-Ares, Luis G. ; Ciuleanu, Tudor-Eliade ; Pluzanski, Adam...
Journal of Thoracic Oncology. 18 (2023) 1 - p. 79-92 , 2023

Link: https://doi.org/10.1016/..

9

First-line nivolumab plus ipilimumab for metastatic non-sma..:

Ready, Neal E ; Audigier-Valette, Clarisse ; Goldman, Jonathan W...
Journal for ImmunoTherapy of Cancer. 11 (2023) 2 - p. e006127 , 2023

Link: https://doi.org/10.1136/..

10

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-..:

Cascone, Tina ; Kar, Gozde ; Spicer, Jonathan D....
Cancer Discovery. 13 (2023) 11 - p. 2394-2411 , 2023

Link: https://doi.org/10.1158/..

11

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topote..:

Johnson, Melissa L ; Patel, Manish R ; Aljumaily, Raid...
The Oncologist. 28 (2023) 7 - p. 640-e559 , 2023

Link: https://doi.org/10.1093/..

12

A phase Ib study of adavosertib, a selective Wee1 inhibitor..:

Falchook, Gerald S ; Sachdev, Jasgit ; Imedio, Esteban Rodrigo...
Investigational New Drugs. 41 (2023) 3 - p. 493-502 , 2023

Link: https://doi.org/10.1007/..

13

Camonsertib in DNA damage response-deficient advanced solid..:

Yap, Timothy A. ; Fontana, Elisa ; Lee, Elizabeth K....
Nature Medicine. 29 (2023) 6 - p. 1400-1411 , 2023

Link: https://doi.org/10.1038/..

14

A randomized phase II study of metronomic cyclophosphamide ..:

Mayer, Erica L. ; Tayob, Nabihah ; Ren, Siyang...
Breast Cancer Research and Treatment. , 2023

Link: https://doi.org/10.1007/..

15

A Phase Ib Study Assessing the Safety, Tolerability, and Ef..:

Bauer, Todd M. ; Moore, Kathleen N. ; Rader, Janet S....
Targeted Oncology. 18 (2023) 4 - p. 517-530 , 2023

Link: https://doi.org/10.1007/..